

Supplementary Materials

Supplementary Methods

Flow cytometry

Thy/Liv implants were analyzed by flow cytometry for assessment of thymocyte subpopulation percentages and implant quality, and data for individual mice in each cohort are shown in Supplementary Tables 1–13.

Single-cell suspensions were made by placing the implant into a sterile nylon mesh bag, submerging the bag in phosphate-buffered saline (PBS)/2% fetal bovine serum (FBS) in a 60 mm tissue culture dish, and dispersing the tissue between the nylon layers with forceps. The cells were counted with a Coulter counter to determine total implant cellularity, and 10^6 cells per well were surface stained with anti-CD4 PE-Cy7 (BD Biosciences), anti-CD8 PE-Cy5.5 (Caltag Laboratories), and anti-CD3 APC-Cy7 (eBiosciences). Following cell surface staining, cells were fixed and permeabilized with 1.2% paraformaldehyde and 0.5% Tween 20, stained with anti-p24 FITC (Beckman Coulter), and analyzed on a LSR II flow cytometer (BD Biosciences). After collecting 100,000 total cell events, percentages of CD4⁺ single positive, CD8⁺ single positive and CD4⁺CD8⁺ double-positive (DP) thymocytes in the implant samples were determined by first gating on a live lymphoid cell population identified by forward- and side-scatter characteristics, and then by gating for CD3 expression. CD4/CD8 ratios were calculated by dividing the percentage of CD4⁺ cells by the percentage of CD8⁺ cells for each individual implant.

Supplementary Table 1. Data for individual mice in Figure 2A (cohort generated with tissues from donor A).

Drug	Drug dose (µg/dose)	Mouse ID	Drug route	p24 (pg/10 ⁶ cells)	HIV RNA (log ₁₀ copies/10 ⁶ cells)	Thy/Liv Implant Cells				Total cell yield (x 10 ⁶)
						CD4 ⁺ CD8 ⁺ Double-positive (%)	CD4 Single-positive (%)	CD8 Single-positive (%)	CD4/CD8 ratio	
NA	Untreated	36	NA	33.0	4.79	84.8	8.9	3.0	2.9	63
NA	Untreated	37	NA	107.7	4.62	80.8	8.5	3.5	2.4	486
NA	Untreated	38	NA	49.5	5.12	82.5	6.8	3.2	2.1	463
NA	Untreated	39	NA	21.0	4.76	67.8	8.6	3.5	2.4	191
NA	Untreated	40	NA	122.8	4.23	80.4	7.9	3.7	2.1	1140
NA	Untreated	41	NA	148.9	4.40	84.5	6.5	3.3	2.0	1042
NA	Untreated	42	NA	39.8	5.26	80.2	7.5	3.2	2.3	925
PG16	1.5	25	i.p.	0.0	1.96	78.2	10.3	3.7	2.8	623
PG16	1.5	26	i.p.	0.0	3.24	82.3	8.4	3.3	2.5	402
PG16	1.5	27	i.p.	0.0	<1.48	77.3	9.1	3.4	2.7	481
PG16	1.5	28*	i.p.	ND	ND	ND	ND	ND	ND	ND
PG16	1.5	29	i.p.	0.0	<1.48	76.1	10.6	3.8	2.8	540
PG16	1.5	30	i.p.	0.0	<1.48	83.0	6.4	2.8	2.3	860
PG16	5	19	i.p.	0.0	<1.48	75.2	12.0	4.2	2.9	253
PG16	5	20	i.p.	0.0	1.50	73.8	11.2	4.6	2.4	740
PG16	5	21	i.p.	0.0	2.34	74.8	12.1	4.3	2.8	408
PG16	5	22	i.p.	11.8	3.89	76.9	9.9	4.2	2.4	883
PG16	5	23	i.p.	0.0	<1.48	88.4	4.4	2.2	2.0	76
PG16	5	24	i.p.	0.0	<1.48	83.7	6.5	2.6	2.5	1140
PG16	15	13*	i.p.	ND	ND	ND	ND	ND	ND	ND
PG16	15	14	i.p.	0.0	<1.48	81.9	7.7	3.1	2.6	394
PG16	15	15†	i.p.	ND	ND	ND	ND	ND	ND	ND
PG16	15	16	i.p.	0.0	<1.48	82.4	7.2	3.3	2.2	823
PG16	15	17	i.p.	0.0	1.51	80.4	7.6	3.3	2.3	1487
PG16	15	18	i.p.	0.0	<1.48	74.6	10.4	3.7	2.8	762
PG16	50	7	i.p.	0.0	<1.48	74.7	11.6	4.9	2.4	571
PG16	50	8	i.p.	0.0	<1.48	79.9	10.2	3.8	2.7	304
PG16	50	9	i.p.	0.0	<1.48	77.5	10.6	4.6	2.3	178
PG16	50	10*	i.p.	ND	ND	ND	ND	ND	ND	ND
PG16	50	11	i.p.	0.0	2.14	35.3	22.4	26.8	0.8	14
PG16	50	12	i.p.	0.0	<1.48	83.7	6.7	3.1	2.2	667
PG16	150	1	i.p.	0.0	<1.48	78.6	9.1	3.8	2.4	1002
PG16	150	2*	i.p.	ND	ND	ND	ND	ND	ND	ND
PG16	150	3	i.p.	0.0	<1.48	77.8	9.1	4.2	2.2	490
PG16	150	4	i.p.	0.0	<1.48	81.3	9.1	3.8	2.4	622
PG16	150	5	i.p.	0.0	<1.48	78.4	8.8	3.4	2.6	790
PG16	150	6	i.p.	0.0	2.01	81.5	7.9	3.6	2.2	382
3TC	30 mg/kg/day	31	i.p.	0.0	<1.48	83.5	7.3	2.9	2.5	672
3TC	30 mg/kg/day	32	i.p.	0.0	<1.48	85.3	6.6	2.7	2.4	360
3TC	30 mg/kg/day	33	i.p.	0.0	2.25	90.2	4.8	1.7	2.9	666
3TC	30 mg/kg/day	34	i.p.	0.0	<1.48	77.1	10.6	4.2	2.5	497
3TC	30 mg/kg/day	35	i.p.	0.0	2.39	81.7	8.2	3.1	2.7	633
NA	Mock-infected	43	NA	0.0	<1.48	68.9	15.9	7.1	2.2	329
NA	Mock-infected	44*	NA	ND	ND	ND	ND	ND	ND	ND
NA	Mock-infected	45	NA	0.0	<1.48	80.6	7.9	3.6	2.2	820
NA	Mock-infected	46	NA	0.0	<1.48	77.1	9.9	3.8	2.6	704
NA	Mock-infected	47	NA	0.0	<1.48	81.2	9.0	3.8	2.4	598

NA: Not applicable

ND: Not determined

* mouse died

† abnormal implant

Supplementary Table 2. Data for individual mice in Figure 2B (cohort generated with tissues from donor B).

Drug	Drug dose (µg/dose)	Mouse ID	Drug route	p24 (pg/10 ⁶ cells)	HIV RNA (log ₁₀ copies/10 ⁶ cells)	Thy/Liv Implant Cells				Total cell yield (x 10 ⁶)
						CD4 ⁺ CD8 ⁺ Double-positive (%)	CD4 Single-positive (%)	CD8 Single-positive (%)	CD4/CD8 ratio	
NA	Untreated	36*	NA	ND	ND	ND	ND	ND	ND	ND
NA	Untreated	37*	NA	ND	ND	ND	ND	ND	ND	ND
NA	Untreated	38	NA	423.1	5.32	35.7	16.9	13.0	1.3	15
NA	Untreated	39	NA	447.0	5.16	70.0	11.2	8.4	1.3	36
NA	Untreated	40	NA	250.2	4.85	74.9	8.6	7.1	1.2	27
NA	Untreated	41	NA	262.7	4.87	72.1	9.9	7.8	1.3	29
NA	Untreated	42	NA	104.8	4.78	78.3	9.6	4.6	2.1	86
PG16	0.05	15	i.p.	480.0	5.16	49.9	20.3	12.6	1.6	25
PG16	0.05	16	i.p.	324.6	3.67	20.9	4.7	4.8	1.0	33
PG16	0.05	17	i.p.	273.5	4.90	63.0	12.6	11.4	1.1	21
PG16	0.05	18*	i.p.	ND	ND	ND	ND	ND	ND	ND
PG16	0.05	19	i.p.	264.2	3.77	47.9	6.8	6.3	1.1	57
PG16	0.05	20	i.p.	279.1	5.26	64.4	7.9	6.2	1.3	130
PG16	0.05	21	i.p.	318.2	5.07	67.1	12.1	8.4	1.4	53
PG16	0.5	8	i.p.	283.9	5.33	65.4	10.2	8.0	1.3	58
PG16	0.5	9	i.p.	750.9	5.14	21.7	36.8	17.6	2.1	24
PG16	0.5	10	i.p.	48.6	4.79	83.2	8.3	3.4	2.4	35
PG16	0.5	11	i.p.	294.1	5.04	8.6	16.1	9.6	1.7	9
PG16	0.5	12*	i.p.	ND	ND	ND	ND	ND	ND	ND
PG16	0.5	13	i.p.	425.0	4.86	79.5	6.2	5.0	1.2	39
PG16	0.5	14	i.p.	312.9	5.04	79.2	7.1	5.4	1.3	45
PG16	5.0	1	i.p.	0.0	<1.48	64.4	18.4	7.1	2.6	88
PG16	5.0	2	i.p.	0.0	2.18	81.2	9.1	3.0	3.0	252
PG16	5.0	3	i.p.	28.5	4.57	81.9	7.3	2.4	3.1	122
PG16	5.0	4	i.p.	0.0	3.47	85.2	7.6	2.1	3.6	240
PG16	5.0	5*	i.p.	ND	ND	ND	ND	ND	ND	ND
PG16	5.0	6	i.p.	154.4	3.79	71.8	12.9	5.0	2.6	49
PG16	5.0	7†	i.p.	ND	ND	ND	ND	ND	ND	ND
Truvada	200/130 mg/kg	29	oral	464.3	5.20	71.2	12.8	7.8	1.6	53
Truvada	200/130 mg/kg	30	oral	0.0	4.31	30.0	9.1	46.2	0.2	4
Truvada	200/130 mg/kg	31	oral	235.2	4.70	82.2	7.1	4.0	1.7	52
Truvada	200/130 mg/kg	32	oral	127.8	4.45	82.4	6.6	4.7	1.4	145
Truvada	200/130 mg/kg	33	oral	143.2	4.51	82.9	6.6	3.5	1.9	120
Truvada	200/130 mg/kg	34	oral	246.3	4.69	79.3	8.4	5.0	1.7	90
Truvada	200/130 mg/kg	35	oral	259.4	4.65	78.2	7.7	4.3	1.8	79
Truvada	2000/1300 mg/kg	22	oral	0.0	1.49	33.6	1.9	1.5	1.3	152
Truvada	2000/1300 mg/kg	23	oral	85.4	4.92	79.3	9.1	5.1	1.8	21
Truvada	2000/1300 mg/kg	24	oral	192.9	5.17	70.7	12.1	7.8	1.5	25
Truvada	2000/1300 mg/kg	25	oral	136.0	4.33	75.4	10.4	4.6	2.3	126
Truvada	2000/1300 mg/kg	26*	oral	ND	ND	ND	ND	ND	ND	ND
Truvada	2000/1300 mg/kg	27	oral	279.8	4.96	78.1	8.0	4.6	1.7	56
Truvada	2000/1300 mg/kg	28	oral	41.4	3.51	65.8	6.6	3.3	2.0	74
NA	Mock-infected	43	NA	0.0	<1.48	86.1	6.8	2.5	2.7	230
NA	Mock-infected	44	NA	0.0	<1.48	86.7	7.7	2.2	3.5	87
NA	Mock-infected	45	NA	0.0	<1.48	89.9	5.7	1.7	3.4	76
NA	Mock-infected	46	NA	0.0	<1.48	81.4	9.4	3.2	2.9	31
NA	Mock-infected	47	NA	0.0	<1.48	88.9	5.4	1.7	3.1	200
NA	Mock-infected	48†	NA	ND	ND	ND	ND	ND	ND	ND
NA	Mock-infected	49	NA	0.0	<1.48	87.2	6.6	2.0	3.3	180

NA: Not applicable

ND: Not determined

* mouse died

† abnormal implant

Supplementary Table 3. Data for individual mice in Figure 2C (cohort generated with tissues from donor C).

Drug	5 µg dose (days before inoculation)	Mouse ID	Drug route	p24 (pg/10 ⁶ cells)	HIV RNA (log ₁₀ copies/ 10 ⁶ cells)	Thy/Liv Implant Cells				Total cell yield (x 10 ⁶)
						CD4 ⁺ CD8 ⁺ Double- positive (%)	CD4 Single- positive (%)	CD8 Single- positive (%)	CD4/CD8 ratio	
NA	Untreated	22	NA	53.0	4.82	71.4	12.5	10.5	1.2	39
NA	Untreated	23	NA	93.4	5.14	74.8	8.8	8.4	1.0	122
NA	Untreated	24	NA	69.1	5.10	65.8	14.4	9.1	1.6	143
NA	Untreated	25	NA	32.7	4.72	78.5	7.6	8.1	0.9	57
NA	Untreated	26	NA	43.6	4.61	79.3	7.6	7.5	1.0	46
NA	Untreated	27	NA	40.9	4.86	73.8	9.7	8.6	1.1	164
NA	Untreated	28	NA	48.1	5.03	74.7	7.5	7.9	1.0	67
PG16	-14	1	i.p.	62.5	4.51	72.7	11.1	8.2	1.4	70
PG16	-14	2	i.p.	51.6	4.67	68.3	13.9	11.4	1.2	192
PG16	-14	3	i.p.	45.5	4.77	70.0	13.9	9.6	1.5	101
PG16	-14	4	i.p.	41.9	4.54	72.5	11.6	9.9	1.2	123
PG16	-14	5	i.p.	23.6	4.31	77.1	9.1	8.2	1.1	112
PG16	-14	6	i.p.	37.8	4.69	73.5	10.3	9.5	1.1	257
PG16	-14	7	i.p.	49.5	4.71	74.7	11.7	8.5	1.4	107
PG16	-7	8	i.p.	32.3	4.23	76.1	10.1	8.4	1.2	139
PG16	-7	9	i.p.	18.6	3.79	69.5	11.7	9.8	1.2	50
PG16	-7	10	i.p.	138.2	4.60	63.8	13.4	13.9	1.0	28
PG16	-7	11	i.p.	0.0	3.02	49.3	2.6	4.4	0.6	7
PG16	-7	12	i.p.	174.9	4.53	70.9	12.6	9.0	1.4	79
PG16	-7	13	i.p.	6.3	3.71	73.6	11.0	8.4	1.3	117
PG16	-7	14	i.p.	29.0	4.21	25.5	2.9	3.7	0.8	254
PG16	-1	15	i.p.	0.0	2.22	80.5	6.2	7.9	0.8	93
PG16	-1	16	i.p.	40.8	4.41	34.8	5.1	7.2	0.7	97
PG16	-1	17	i.p.	24.4	3.99	73.7	10.4	8.9	1.2	75
PG16	-1	18	i.p.	0.0	3.01	57.9	15.9	18.1	0.9	45
PG16	-1	19	i.p.	0.0	2.08	73.2	11.6	9.6	1.2	63
PG16	-1	20	i.p.	0.0	3.17	80.1	7.3	7.5	1.0	134
PG16	-1	21	i.p.	0.0	3.05	76.9	8.9	7.3	1.2	132
NA	Mock-infected	29	NA	0.0	<1.48	75.0	8.7	6.9	1.3	101
NA	Mock-infected	30	NA	0.0	<1.48	81.2	7.4	6.8	1.1	178
NA	Mock-infected	31	NA	0.0	<1.48	79.5	7.1	6.1	1.2	181
NA	Mock-infected	32	NA	0.0	<1.48	79.3	7.6	6.6	1.2	201
NA	Mock-infected	33	NA	0.0	<1.48	77.7	8.4	8.3	1.0	69

NA: Not applicable

Supplementary Table 4. Data for individual mice in Figure 3A (cohort generated with tissues from donor D).

Drug	Drug dose (µg/dose)	Mouse ID	Drug route	p24 (pg/10 ⁶ cells)	HIV RNA (log ₁₀ copies/10 ⁶ cells)	Thy/Liv Implant Cells				Total cell yield (x 10 ⁶)
						CD4 ⁺ CD8 ⁺ Double-positive (%)	CD4 Single-positive (%)	CD8 Single-positive (%)	CD4/CD8 ratio	
NA	Untreated	43	NA	898.9	5.23	81.5	5.3	7.2	0.7	88
NA	Untreated	44	NA	599.0	4.73	79.8	6.9	6.5	1.1	65
NA	Untreated	45	NA	725.9	5.74	78.3	7.6	7.5	1.0	30
NA	Untreated	46	NA	6.4	3.58	87.9	5.9	2.6	2.3	76
NA	Untreated	47	NA	397.4	5.00	83.5	6.1	5.4	1.1	75
NA	Untreated	48	NA	1290.6	6.36	74.8	5.5	12.2	0.5	43
NA	Untreated	49	NA	472.0	5.26	82.2	5.2	6.9	0.7	79
Isotype	500	29	i.p.	380.3	4.85	83.5	6.1	5.0	1.2	62
Isotype	500	30	i.p.	722.9	5.36	80.3	5.1	8.0	0.6	33
Isotype	500	31*	i.p.	ND	ND	ND	ND	ND	ND	ND
Isotype	500	32	i.p.	1461.6	6.64	67.5	7.6	14.9	0.5	12
Isotype	500	33*	i.p.	ND	ND	ND	ND	ND	ND	ND
Isotype	500	34	i.p.	933.3	5.98	80.4	4.9	8.4	0.6	44
Isotype	500	35	i.p.	850.3	5.52	78.8	4.7	9.0	0.5	15
PG16	50	22	i.p.	0.0	1.98	79.7	8.1	2.6	3.1	135
PG16	50	23	i.p.	0.0	1.93	86.9	4.4	4.3	1.0	75
PG16	50	24*	i.p.	ND	ND	ND	ND	ND	ND	ND
PG16	50	25	i.p.	0.0	1.90	85.3	6.4	4.4	1.5	100
PG16	50	26	i.p.	0.0	3.53	82.5	8.3	3.9	2.1	158
PG16	50	27	i.p.	0.0	1.91	87.2	6.1	3.3	1.9	128
PG16	50	28	i.p.	0.0	2.44	81.0	9.1	5.6	1.6	17
PG16	150	15	i.p.	0.0	1.78	83.6	8.2	4.9	1.7	131
PG16	150	16	i.p.	0.0	1.87	35.9	4.7	3.0	1.6	84
PG16	150	17	i.p.	0.0	1.80	82.3	8.4	5.4	1.6	55
PG16	150	18	i.p.	0.0	2.05	79.3	11.7	5.5	2.1	24
PG16	150	19	i.p.	0.0	1.61	78.9	11.2	4.7	2.4	76
PG16	150	20	i.p.	0.0	1.83	87.1	6.6	3.0	2.2	26
PG16	150	21	i.p.	0.0	1.86	85.8	7.7	3.6	2.1	119
PG16	500	8	i.p.	0.0	1.90	30.6	4.5	1.9	2.4	180
PG16	500	9	i.p.	0.0	1.62	82.6	8.5	5.6	1.5	68
PG16	500	10	i.p.	0.0	1.69	84.1	7.6	4.3	1.8	219
PG16	500	11	i.p.	0.0	1.82	86.7	6.2	4.6	1.3	36
PG16	500	12	i.p.	0.0	1.85	84.0	7.4	4.8	1.6	146
PG16	500	13	i.p.	0.0	1.70	82.7	6.9	5.0	1.4	134
PG16	500	14	i.p.	0.0	2.66	76.5	7.3	4.6	1.6	8
PG9	500	1	i.p.	0.0	1.77	83.9	7.6	4.8	1.6	73
PG9	500	2	i.p.	0.0	1.80	86.1	5.7	4.3	1.3	39
PG9	500	3	i.p.	0.0	3.19	85.6	6.2	4.0	1.6	13
PG9	500	4	i.p.	38.3	3.73	85.0	6.2	4.8	1.3	151
PG9	500	5	i.p.	42.4	3.92	85.5	6.3	4.2	1.5	29
PG9	500	6	i.p.	0.0	2.13	84.4	7.2	4.2	1.7	167
PG9	500	7	i.p.	0.0	1.64	82.4	7.2	5.0	1.5	199
3TC	30 mg/kg/day	36	i.p.	0.0	3.04	88.4	5.0	3.3	1.5	44
3TC	30 mg/kg/day	37	i.p.	0.0	2.03	85.3	6.4	3.5	1.8	134
3TC	30 mg/kg/day	38	i.p.	0.0	3.55	86.7	6.4	3.1	2.1	71
3TC	30 mg/kg/day	39	i.p.	0.0	1.52	86.6	5.4	4.0	1.3	43
3TC	30 mg/kg/day	40	i.p.	0.0	2.05	86.9	6.0	4.0	1.5	213
3TC	30 mg/kg/day	41	i.p.	28.9	3.36	85.0	7.3	4.1	1.8	32
3TC	30 mg/kg/day	42	i.p.	0.0	2.52	87.7	5.0	3.7	1.3	57
NA	Mock-infected	50	NA	0.0	<2.18	70.6	4.7	9.2	0.5	4
NA	Mock-infected	51	NA	0.0	<1.48	85.3	5.6	4.2	1.3	69
NA	Mock-infected	52	NA	0.0	<1.48	87.5	6.3	3.4	1.9	111
NA	Mock-infected	53	NA	0.0	<1.48	86.3	6.3	3.0	2.1	168
NA	Mock-infected	54	NA	0.0	<1.48	87.5	5.8	2.9	2.0	124

NA: Not applicable

ND: Not determined

* mouse died

Supplementary Table 5. Data for individual mice in Figure 3B (cohort generated with tissues from donor E).

Drug	Drug dose (µg/dose)	Mouse ID	Drug route	p24 (pg/10 ⁶ cells)	HIV RNA (log ₁₀ copies/10 ⁶ cells)	Thy/Liv Implant Cells				Total cell yield (x 10 ⁶)
						CD4 ⁺ CD8 ⁺ Double-positive (%)	CD4 Single-positive (%)	CD8 Single-positive (%)	CD4/CD8 ratio	
NA	Untreated	36	NA	1242.1	6.22	73.7	7.0	8.9	0.8	57
NA	Untreated	37	NA	1315.5	5.92	79.0	7.6	6.8	1.1	661
NA	Untreated	38	NA	1094.7	6.05	75.4	5.3	6.8	0.8	469
NA	Untreated	39	NA	752.9	6.05	68.4	5.2	15.4	0.3	132
NA	Untreated	40	NA	1048.5	6.09	48.3	4.4	6.0	0.7	164
NA	Untreated	41	NA	702.2	6.60	74.6	5.5	11.1	0.5	79
NA	Untreated	42	NA	50.7	4.25	85.2	5.8	4.2	1.4	378
PG16	1.5	25	i.p.	10.3	4.05	83.4	7.4	4.1	1.8	798
PG16	1.5	26	i.p.	0.0	2.19	81.5	6.5	4.1	1.6	732
PG16	1.5	27	i.p.	0.0	2.95	80.1	6.2	3.4	1.8	391
PG16	1.5	28	i.p.	0.0	2.50	3.1	8.8	12.9	0.7	8
PG16	1.5	29	i.p.	0.0	2.62	81.8	8.0	4.0	2.0	428
PG16	1.5	30	i.p.	0.0	1.67	65.1	4.4	3.4	1.3	424
PG16	5	19	i.p.	0.0	<1.48	80.9	9.7	5.2	1.9	171
PG16	5	20	i.p.	0.0	3.74	77.5	7.6	5.2	1.5	913
PG16	5	21	i.p.	0.0	3.45	83.0	6.9	3.9	1.8	214
PG16	5	22	i.p.	0.0	2.27	77.9	10.8	5.3	2.1	483
PG16	5	23	i.p.	0.0	2.88	84.2	6.5	3.8	1.7	474
PG16	5	24	i.p.	0.0	2.12	81.4	7.1	5.0	1.4	691
PG16	15	13	i.p.	0.0	2.86	83.9	7.4	4.0	1.9	513
PG16	15	14	i.p.	0.0	2.20	86.0	6.4	3.5	1.8	797
PG16	15	15	i.p.	0.0	2.33	37.5	2.4	1.9	1.3	594
PG16	15	16	i.p.	0.0	<1.48	6.1	0.4	0.4	1.2	568
PG16	15	17	i.p.	0.0	1.82	84.3	7.0	4.7	1.5	93
PG16	15	18	i.p.	0.0	3.54	86.8	5.8	4.1	1.4	141
PG16	50	7	i.p.	0.0	<1.48	80.8	6.0	3.9	1.5	217
PG16	50	8	i.p.	0.0	<1.48	76.8	8.8	4.4	2.0	1197
PG16	50	9	i.p.	0.0	<1.48	79.9	8.7	4.2	2.0	763
PG16	50	10	i.p.	0.0	3.29	71.2	14.8	6.1	2.4	1295
PG16	50	11	i.p.	0.0	2.81	76.8	12.2	4.5	2.7	161
PG16	50	12	i.p.	0.0	<1.48	80.7	9.0	5.0	1.8	537
PG16	150	1	i.p.	0.0	2.22	87.7	5.4	3.1	1.7	257
PG16	150	2	i.p.	0.0	3.26	83.0	7.1	4.4	1.6	88
PG16	150	3	i.p.	0.0	1.58	85.1	6.8	3.6	1.9	1831
PG16	150	4	i.p.	0.0	1.79	87.9	5.9	3.3	1.8	257
PG16	150	5	i.p.	0.0	<1.48	80.7	6.0	4.4	1.4	569
PG16	150	6	i.p.	0.0	<1.48	82.7	7.9	4.3	1.9	621
3TC	30 mg/kg/day	31	i.p.	174.7	4.96	80.8	8.3	4.0	2.1	221
3TC	30 mg/kg/day	32	i.p.	44.9	3.63	19.8	1.9	1.7	1.1	386
3TC	30 mg/kg/day	33	i.p.	0.0	3.59	85.9	6.7	2.8	2.4	406
3TC	30 mg/kg/day	34	i.p.	12.4	4.05	86.2	6.8	3.4	2.0	448
3TC	30 mg/kg/day	35	i.p.	16.2	3.59	38.8	4.6	5.3	0.9	67
NA	Mock-infected	43	NA	0.0	<1.48	86.0	6.3	3.4	1.8	597
NA	Mock-infected	44	NA	0.0	<1.48	85.0	6.8	3.7	1.8	945
NA	Mock-infected	45	NA	0.0	<1.48	85.8	6.5	4.0	1.6	572
NA	Mock-infected	46	NA	0.0	<1.48	80.5	6.6	3.9	1.7	795
NA	Mock-infected	47	NA	0.0	<1.48	77.9	6.1	4.5	1.4	831
NA	Mock-infected	48	NA	0.0	<1.48	42.3	2.7	2.0	1.3	417

NA: Not applicable

Supplementary Table 6. Data for individual mice in Figure 3C (cohort generated with tissues from donor F).

Drug	Drug dose (µg/dose)	Mouse ID	Drug route	p24 (pg/10 ⁶ cells)	HIV RNA (log ₁₀ copies/10 ⁶ cells)	Thy/Liv Implant Cells				Total cell yield (x 10 ⁶)
						CD4 ⁺ CD8 ⁺ Double-positive (%)	CD4 Single-positive (%)	CD8 Single-positive (%)	CD4/CD8 ratio	
NA	Untreated	42	NA	389.9	5.14	72.1	7.2	6.9	1.0	287
NA	Untreated	43	NA	125.5	4.42	83.0	5.7	4.4	1.3	189
NA	Untreated	44	NA	123.1	4.53	83.2	5.9	5.9	1.0	49
NA	Untreated	45	NA	219.2	4.51	78.1	4.7	6.7	0.7	24
NA	Untreated	46	NA	413.9	5.33	79.2	5.1	8.2	0.6	27
NA	Untreated	47	NA	68.4	4.90	80.2	7.5	5.9	1.3	302
NA	Untreated	48	NA	250.6	4.55	79.7	7.6	5.9	1.3	236
PG16	0.05	31 [†]	i.p.	ND	ND	ND	ND	ND	ND	ND
PG16	0.05	32	i.p.	110.4	4.19	76.7	7.6	5.9	1.3	182
PG16	0.05	33	i.p.	116.0	4.24	78.1	6.4	6.2	1.0	133
PG16	0.05	34 [†]	i.p.	ND	ND	ND	ND	ND	ND	ND
PG16	0.05	35	i.p.	44.3	4.77	85.7	5.9	3.8	1.6	66
PG16	0.05	36 [†]	i.p.	ND	ND	ND	ND	ND	ND	ND
PG16	0.15	25	i.p.	307.9	4.59	79.5	7.2	8.4	0.9	138
PG16	0.15	26	i.p.	193.3	4.80	73.2	9.3	8.9	1.0	41
PG16	0.15	27	i.p.	17.9	4.32	76.5	8.7	6.8	1.3	19
PG16	0.15	28	i.p.	649.2	5.17	53.8	5.4	4.2	1.3	337
PG16	0.15	29	i.p.	263.2	4.52	81.6	7.6	6.2	1.2	114
PG16	0.15	30	i.p.	169.8	4.48	80.5	6.9	5.8	1.2	220
PG16	0.5	19	i.p.	25.6	4.48	84.0	6.9	4.1	1.7	27
PG16	0.5	20	i.p.	9.9	4.05	80.4	8.4	5.8	1.4	43
PG16	0.5	21	i.p.	0.0	3.60	76.9	11.0	6.1	1.8	74
PG16	0.5	22	i.p.	0.0	4.02	81.0	8.0	4.9	1.6	158
PG16	0.5	23	i.p.	0.0	4.16	78.9	9.7	5.8	1.7	110
PG16	0.5	24 [†]	i.p.	ND	ND	ND	ND	ND	ND	ND
PG16	1.5	13	i.p.	0.0	2.09	84.5	7.1	4.1	1.7	50
PG16	1.5	14	i.p.	0.0	<1.48	83.9	7.6	3.7	2.1	266
PG16	1.5	15	i.p.	0.0	1.74	78.7	9.0	5.3	1.7	211
PG16	1.5	16	i.p.	0.0	1.66	78.7	10.1	5.5	1.8	191
PG16	1.5	17	i.p.	0.0	1.93	68.6	15.7	12.3	1.3	24
PG16	1.5	18	i.p.	0.0	3.24	78.7	9.1	5.2	1.7	114
PG16	5.0	7	i.p.	0.0	<1.48	86.7	5.4	3.6	1.5	67
PG16	5.0	8	i.p.	0.0	2.04	77.7	8.7	5.1	1.7	25
PG16	5.0	9	i.p.	0.0	2.78	82.4	7.2	4.8	1.5	219
PG16	5.0	10	i.p.	0.0	<1.48	81.0	7.7	5.3	1.5	183
PG16	5.0	11 [†]	i.p.	ND	ND	ND	ND	ND	ND	ND
PG16	5.0	12	i.p.	0.0	<1.48	83.3	6.1	3.5	1.8	328
PG16	5.0, once	1	i.p.	0.0	<1.48	76.7	10.3	5.3	2.0	176
PG16	5.0, once	2	i.p.	0.0	1.99	76.7	11.5	5.2	2.2	320
PG16	5.0, once	3	i.p.	0.0	1.85	69.9	8.1	5.1	1.6	11
PG16	5.0, once	4	i.p.	0.0	<1.78	85.3	5.8	4.8	1.2	22
PG16	5.0, once	5	i.p.	0.0	1.51	84.0	7.3	4.1	1.8	127
PG16	5.0, once	6	i.p.	0.0	<1.48	83.7	6.3	3.6	1.8	50
3TC	30 mg/kg/day	37	i.p.	0.0	3.63	81.0	9.1	5.1	1.8	54
3TC	30 mg/kg/day	38	i.p.	0.0	2.08	82.7	7.3	4.5	1.6	30
3TC	30 mg/kg/day	39	i.p.	0.0	2.44	79.5	8.4	4.9	1.7	235
3TC	30 mg/kg/day	40	i.p.	0.0	2.20	83.3	6.7	4.5	1.5	164
3TC	30 mg/kg/day	41	i.p.	0.0	2.57	84.6	6.7	3.2	2.1	138
NA	Mock-infected	49	NA	0.0	<1.48	79.9	9.9	4.9	2.0	164
NA	Mock-infected	50	NA	0.0	<1.48	62.0	4.8	3.2	1.5	140
NA	Mock-infected	51 [†]	NA	ND	ND	ND	ND	ND	ND	ND
NA	Mock-infected	52*	NA	ND	ND	ND	ND	ND	ND	ND
NA	Mock-infected	53	NA	0.0	<2.18	66.5	7.2	4.2	1.7	11
NA	Mock-infected	54	NA	0.0	<1.48	85.8	6.5	3.6	1.8	91

NA: Not applicable

ND: Not determined

* mouse died

† abnormal implant

Supplementary Table 7. Data for individual mice in Figure 4A (cohort generated with tissues from donor G).

Drug	Drug dose (µg/dose)	Mouse ID	Drug route	p24 (pg/10 ⁶ cells)	HIV RNA (log ₁₀ copies/10 ⁶ cells)	Thy/Liv Implant Cells				Total cell yield (x 10 ⁶)
						CD4 ⁺ CD8 ⁺ Double-positive (%)	CD4 Single-positive (%)	CD8 Single-positive (%)	CD4/CD8 ratio	
NA	Untreated	28	NA	1953.6	6.61	42.9	27.7	15.1	1.8	23
NA	Untreated	29	NA	4267.4	6.66	17.0	34.4	22.7	1.5	18
NA	Untreated	30	NA	1924.9	6.76	56.9	19.6	10.7	1.8	39
NA	Untreated	31	NA	1949.1	6.75	67.8	11.5	8.7	1.3	25
NA	Untreated	32*	NA	ND	ND	ND	ND	ND	ND	ND
NA	Untreated	33	NA	0.0	3.38	59.2	8.8	5.1	1.7	83
NA	Untreated	34	NA	3080.3	6.59	17.5	34.5	21.8	1.6	17
PG16	50	15	i.p.	702.1	5.87	4.3	40.1	31.1	1.3	9
PG16	50	16	i.p.	960.3	6.66	65.5	14.4	9.5	1.5	15
PG16	50	17	i.p.	847.0	5.84	47.0	23.2	15.5	1.5	17
PG16	50	18	i.p.	731.2	5.75	12.2	49.1	21.9	2.2	15
PG16	50	19	i.p.	380.9	4.97	75.2	10.9	6.7	1.6	105
PG16	50	20	i.p.	480.5	5.34	6.1	45.2	25.2	1.8	19
PG16	50	21	i.p.	939.4	6.00	40.2	28.6	16.5	1.7	40
PG16	150	8	i.p.	487.0	5.46	66.5	16.4	7.8	2.1	23
PG16	150	9	i.p.	533.8	5.60	8.4	37.5	17.8	2.1	17
PG16	150	10	i.p.	542.8	5.57	20.8	43.9	18.1	2.4	19
PG16	150	11 [†]	i.p.	ND	ND	ND	ND	ND	ND	ND
PG16	150	12	i.p.	854.2	5.73	8.9	42.0	23.4	1.8	15
PG16	150	13	i.p.	926.6	6.36	7.7	46.2	27.5	1.7	21
PG16	150	14	i.p.	504.5	5.56	69.8	12.4	8.3	1.5	33
PG16	500	1	i.p.	703.2	5.73	34.3	33.3	16.9	2.0	22
PG16	500	2	i.p.	741.6	6.00	3.4	46.0	28.5	1.6	9
PG16	500	3	i.p.	1085.6	5.97	6.0	42.5	26.4	1.6	20
PG16	500	4	i.p.	857.5	5.90	35.3	24.6	22.9	1.1	19
PG16	500	5	i.p.	862.4	5.78	46.0	20.1	15.5	1.3	11
PG16	500	6	i.p.	564.1	5.10	14.0	36.4	23.8	1.5	15
PG16	500	7	i.p.	979.5	5.82	7.9	40.0	25.6	1.6	22
3TC	30 mg/kg/day	22	i.p.	0.0	3.00	78.6	9.2	5.5	1.7	24
3TC	30 mg/kg/day	23	i.p.	0.0	2.72	84.0	4.3	4.8	0.9	13
3TC	30 mg/kg/day	24	i.p.	131.7	4.63	50.2	6.0	3.9	1.5	101
3TC	30 mg/kg/day	25	i.p.	0.0	3.12	83.8	7.7	5.3	1.4	17
3TC	30 mg/kg/day	26	i.p.	0.0	2.71	81.0	7.0	4.6	1.5	45
3TC	30 mg/kg/day	27	i.p.	0.0	3.61	81.5	5.6	4.3	1.3	11
PG16	500, Mock-infected	35	i.p.	0.0	<2.18	88.9	6.2	2.0	3.1	7
PG16	500, Mock-infected	36	i.p.	0.0	<1.48	84.5	8.0	2.9	2.7	341
PG16	500, Mock-infected	37	i.p.	0.0	<1.48	86.7	6.3	3.1	2.0	140
PG16	500, Mock-infected	38	i.p.	0.0	<1.48	81.8	8.6	3.6	2.4	58
PG16	500, Mock-infected	39	i.p.	ND	ND	89.6	5.1	2.2	2.3	107
PG16	500, Mock-infected	40	i.p.	0.0	<1.48	65.9	16.4	9.0	1.8	43
PG16	500, Mock-infected	41	i.p.	0.0	<1.48	88.1	5.5	2.5	2.2	34
NA	Mock-infected	42	NA	0.0	<2.18	19.4	14.8	2.9	5.1	13
NA	Mock-infected	43	NA	0.0	<1.48	79.6	9.0	3.5	2.6	87
NA	Mock-infected	44	NA	0.0	<1.48	85.0	8.0	2.7	3.0	158
NA	Mock-infected	45	NA	0.0	<1.48	87.6	4.8	2.1	2.3	81
NA	Mock-infected	46	NA	0.0	<1.48	86.1	6.4	3.2	2.0	141
NA	Mock-infected	47	NA	0.0	<1.48	67.2	5.3	3.9	1.4	120

NA: Not applicable

ND: Not determined

* mouse died

† abnormal implant

Supplementary Table 8. Data for individual mice in Figure 4B (cohort generated with tissues from donor H).

Drug	Drug dose (µg/dose)	Mouse ID	Drug route	p24 (pg/10 ⁶ cells)	HIV RNA (log ₁₀ copies/10 ⁶ cells)	Thy/Liv Implant Cells				Total cell yield (x 10 ⁶)
						CD4 ⁺ CD8 ⁺ Double-positive (%)	CD4 Single-positive (%)	CD8 Single-positive (%)	CD4/CD8 ratio	
NA	Untreated	27	NA	2288.3	6.45	66.1	15.0	9.2	1.6	80
NA	Untreated	28	NA	100.5	5.47	72.5	14.5	6.6	2.2	ND
NA	Untreated	29	NA	0.0	3.46	81.6	7.4	4.4	1.7	216
NA	Untreated	30	NA	1921.3	6.73	24.6	31.2	23.3	1.3	25
NA	Untreated	31	NA	2293.3	6.96	49.6	22.3	15.8	1.4	51
NA	Untreated	32	NA	2782.9	6.92	58.9	19.7	11.4	1.7	59
NA	Untreated	33	NA	2229.7	6.92	48.1	21.0	16.9	1.2	99
PG9	50	15	i.p.	191.1	4.57	75.2	11.4	4.8	2.4	71
PG9	50	16	i.p.	75.9	5.04	81.7	9.2	4.1	2.2	99
PG9	50	17	i.p.	117.4	4.48	84.8	6.9	4.6	1.5	168
PG9	50	18	i.p.	224.1	4.50	65.1	17.8	9.1	2.0	68
PG9	50	19	i.p.	153.7	4.38	79.3	9.9	6.1	1.6	135
PG9	50	20	i.p.	615.4	5.40	73.4	9.0	5.9	1.5	63
PG9	50	21	i.p.	316.3	5.20	73.1	8.3	5.7	0.0	208
PG9	150	8	i.p.	74.1	4.33	68.2	11.9	8.6	1.4	16
PG9	150	9	i.p.	104.4	4.23	77.7	8.3	5.6	1.5	151
PG9	150	10	i.p.	146.0	4.58	76.7	8.5	6.0	1.4	115
PG9	150	11	i.p.	157.8	4.47	81.6	8.4	5.3	1.6	318
PG9	150	12	i.p.	339.8	4.84	78.1	8.6	6.7	1.3	208
PG9	150	13	i.p.	448.0	5.19	82.1	7.5	5.9	1.3	58
PG9	150	14	i.p.	872.0	5.78	73.7	9.9	6.3	0.0	220
PG9	500	1	i.p.	66.5	4.19	78.1	6.1	5.2	1.2	225
PG9	500	2	i.p.	82.1	4.99	76.5	7.5	6.3	1.2	106
PG9	500	3	i.p.	52.2	4.03	76.0	7.8	4.1	1.9	185
PG9	500	4	i.p.	192.7	4.26	79.5	6.4	6.3	1.0	201
PG9	500	5	i.p.	95.1	5.25	77.8	8.1	6.3	1.3	100
PG9	500	6 [†]	i.p.	ND	ND	ND	ND	ND	ND	ND
PG9	500	7	i.p.	612.2	5.41	76.0	8.5	6.3	1.3	284
3TC	30 mg/kg/day	22	i.p.	178.2	4.52	80.7	9.2	5.1	1.8	122
3TC	30 mg/kg/day	23	i.p.	195.1	4.56	77.1	7.4	4.0	1.8	134
3TC	30 mg/kg/day	24	i.p.	123.7	4.28	84.2	5.0	3.1	1.6	193
3TC	30 mg/kg/day	25	i.p.	88.2	5.24	82.7	5.9	5.1	1.2	30
3TC	30 mg/kg/day	26	i.p.	0.0	2.88	82.9	6.1	3.4	1.8	118
PG9	150, Mock-infected	41	i.p.	0.0	<1.48	49.9	4.1	5.0	0.8	321
PG9	150, Mock-infected	42	i.p.	0.0	<1.48	86.1	6.3	3.3	1.9	47
PG9	150, Mock-infected	43	i.p.	0.0	<1.48	85.2	6.0	4.9	1.2	418
PG9	150, Mock-infected	44	i.p.	0.0	<1.48	85.4	6.0	4.7	1.3	119
PG9	150, Mock-infected	45	i.p.	0.0	<1.48	78.8	7.6	4.1	1.9	324
PG9	150, Mock-infected	46	i.p.	0.0	<1.48	85.9	6.5	3.5	1.8	140
PG9	500, Mock-infected	34	i.p.	0.0	<1.48	82.7	5.3	2.8	1.9	368
PG9	500, Mock-infected	35	i.p.	0.0	<1.48	83.2	6.3	5.3	1.2	262
PG9	500, Mock-infected	36	i.p.	0.0	<1.48	82.2	7.2	4.8	1.5	273
PG9	500, Mock-infected	37	i.p.	0.0	<1.48	84.0	6.7	4.5	1.5	361
PG9	500, Mock-infected	38	i.p.	0.0	<1.48	81.2	10.0	6.2	1.6	82
PG9	500, Mock-infected	39	i.p.	0.0	<1.48	83.4	7.1	5.8	1.2	ND
PG9	500, Mock-infected	40	i.p.	0.0	<1.48	81.8	7.0	3.9	1.8	180
NA	NA	47	NA	0.0	<1.48	84.0	7.4	5.0	1.5	115
NA	NA	48	NA	0.0	<1.48	85.0	6.9	4.4	1.6	108
NA	NA	49	NA	0.0	<1.48	81.5	7.9	6.1	1.3	225
NA	NA	50	NA	0.0	<1.48	85.5	6.6	4.3	1.5	276

NA: Not applicable

ND: Not determined

[†] abnormal implant

Supplementary Table 9. Data for individual mice in Figure 5A (cohort generated with tissues from donor I).

Drug	Drug dose (µg/dose)	Mouse ID	Drug route	p24 (pg/10 ⁶ cells)	HIV RNA (log ₁₀ copies/10 ⁶ cells)	Thy/Liv Implant Cells				Total cell yield (x 10 ⁶)
						CD4 ⁺ CD8 ⁺ Double-positive (%)	CD4 Single-positive (%)	CD8 Single-positive (%)	CD4/CD8 ratio	
NA	Untreated	36	NA	318.0	5.08	57.2	18.2	8.9	2.0	85
NA	Untreated	37	NA	172.8	4.79	61.5	14.6	10.3	1.4	45
NA	Untreated	38	NA	ND	4.99	41.2	11.5	12.3	0.9	12
NA	Untreated	39	NA	116.6	4.90	56.6	18.7	11.1	1.7	121
NA	Untreated	40	NA	280.3	5.25	55.3	18.3	11.5	1.6	102
NA	Untreated	41	NA	342.8	5.35	66.9	14.2	6.0	2.4	332
NA	Untreated	42*	NA	ND	ND	ND	ND	ND	ND	ND
PG16	1.5	22	i.p.	169.2	5.01	74.1	11.6	4.1	2.9	73
PG16	1.5	23	i.p.	83.6	4.94	66.9	15.9	6.4	2.5	503
PG16	1.5	24	i.p.	130.3	4.65	73.0	11.6	5.2	2.2	150
PG16	1.5	25	i.p.	156.8	4.94	74.6	11.0	4.3	2.6	119
PG16	1.5	26	i.p.	161.6	5.07	73.2	13.5	3.7	3.6	323
PG16	1.5	27	i.p.	119.7	4.74	60.8	19.5	6.4	3.0	144
PG16	1.5	28	i.p.	196.3	4.85	57.4	21.6	7.5	2.9	221
PG16	5.0	15	i.p.	181.5	4.20	65.8	17.5	5.3	3.3	401
PG16	5.0	16	i.p.	52.6	4.14	67.0	15.5	6.8	2.3	124
PG16	5.0	17	i.p.	137.8	4.58	78.2	10.0	5.1	2.0	177
PG16	5.0	18	i.p.	129.5	4.59	61.0	14.7	12.5	1.2	96
PG16	5.0	19	i.p.	171.7	4.96	73.3	10.7	4.9	2.2	551
PG16	5.0	20	i.p.	0.0	2.80	74.4	11.4	4.7	2.4	682
PG16	5.0	21	i.p.	127.4	4.37	70.1	13.6	4.6	2.9	319
PG16	15	8 [†]	i.p.	ND	ND	ND	ND	ND	ND	ND
PG16	15	9 [†]	i.p.	ND	ND	ND	ND	ND	ND	ND
PG16	15	10	i.p.	68.5	4.46	73.8	7.4	2.6	2.9	206
PG16	15	11	i.p.	248.8	4.46	61.0	18.0	6.9	2.6	171
PG16	15	12	i.p.	0.0	1.52	76.1	10.6	3.9	2.8	339
PG16	15	13	i.p.	83.7	4.82	65.4	16.9	5.8	2.9	251
PG16	15	14	i.p.	150.2	4.29	72.9	10.8	4.3	2.5	345
PG16	50	1	i.p.	189.2	4.62	71.1	14.5	4.0	3.7	324
PG16	50	2	i.p.	145.1	4.91	74.1	9.2	4.8	1.9	201
PG16	50	3	i.p.	84.9	4.37	75.9	7.0	3.8	1.8	171
PG16	50	4	i.p.	0.0	<1.48	66.5	19.0	6.7	2.8	87
PG16	50	5*	i.p.	ND	ND	ND	ND	ND	ND	ND
PG16	50	6	i.p.	197.4	4.73	69.6	15.2	6.6	2.3	344
PG16	50	7	i.p.	162.3	4.94	57.9	18.0	8.5	2.1	62
Truvada	2000/1300 mg/kg	29	oral	218.7	4.80	67.5	14.6	6.1	2.4	811
Truvada	2000/1300 mg/kg	30	oral	443.1	5.31	58.5	18.6	7.0	2.7	281
Truvada	2000/1300 mg/kg	31	oral	90.3	4.31	78.2	10.4	3.4	3.1	627
Truvada	2000/1300 mg/kg	32	oral	113.3	4.88	64.9	16.9	7.1	2.4	227
Truvada	2000/1300 mg/kg	33	oral	218.9	4.87	61.3	15.4	6.5	2.4	155
Truvada	2000/1300 mg/kg	34	oral	187.8	4.96	72.1	10.7	4.3	2.5	140
Truvada	2000/1300 mg/kg	35	oral	194.6	4.67	70.2	13.3	5.3	2.5	271
NA	Mock-infected	43*	NA	ND	ND	ND	ND	ND	ND	ND
NA	Mock-infected	44	NA	0.0	<1.48	77.2	11.9	3.2	3.8	1067
NA	Mock-infected	45	NA	0.0	<1.48	63.2	24.5	4.1	6.0	33
NA	Mock-infected	46	NA	0.0	<1.48	78.1	11.6	3.2	3.6	898
NA	Mock-infected	47	NA	0.0	<1.48	80.0	10.4	2.1	4.9	559
NA	Mock-infected	48	NA	0.0	<1.48	81.0	9.5	3.0	3.2	237
NA	Mock-infected	49	NA	0.0	<1.48	79.6	10.4	3.9	2.7	679

NA: Not applicable

ND: Not determined

* mouse died

† abnormal implant

Supplementary Table 10. Data for individual mice in Figure 5B (cohort generated with tissues from donor J).

Drug	Drug dose (µg/dose)	Mouse ID	Drug route	p24 (pg/10 ⁶ cells)	HIV RNA (log ₁₀ copies/10 ⁶ cells)	Thy/Liv Implant Cells				Total cell yield (x 10 ⁶)
						CD4 ⁺ CD8 ⁺ Double-positive (%)	CD4 Single-positive (%)	CD8 Single-positive (%)	CD4/CD8 ratio	
NA	Untreated	36	NA	70.1	4.78	75.5	10.9	5.4	2.0	100
NA	Untreated	37	NA	57.7	4.54	81.4	8.1	4.6	1.8	70
NA	Untreated	38	NA	66.3	4.42	77.5	7.6	3.9	2.0	130
NA	Untreated	39	NA	31.0	3.87	80.0	8.4	4.2	2.0	49
NA	Untreated	40	NA	117.4	4.60	71.6	13.5	6.1	2.2	90
NA	Untreated	41	NA	56.0	4.32	73.0	11.7	7.1	1.7	50
NA	Untreated	42	NA	92.8	5.03	70.9	9.6	5.7	1.7	115
PG16	1.5	22	i.p.	75.9	4.58	83.5	7.1	4.5	1.6	200
PG16	1.5	23	i.p.	53.8	4.81	77.9	8.5	4.6	1.9	181
PG16	1.5	24	i.p.	31.1	4.47	78.8	7.7	4.5	1.7	170
PG16	1.5	25	i.p.	34.4	4.62	69.9	6.4	3.2	2.0	71
PG16	1.5	26	i.p.	48.5	4.66	81.4	7.3	4.3	1.7	78
PG16	1.5	27	i.p.	28.5	4.59	79.7	8.6	4.6	1.9	19
PG16	1.5	28	i.p.	66.3	3.87	37.8	12.0	5.8	2.1	36
PG16	5.0	15	i.p.	55.0	3.92	81.9	7.9	5.0	1.6	60
PG16	5.0	16	i.p.	86.9	4.49	78.6	7.1	4.4	1.6	72
PG16	5.0	17	i.p.	58.8	4.74	71.3	12.1	5.3	2.3	139
PG16	5.0	18 [†]	i.p.	ND	ND	ND	ND	ND	ND	ND
PG16	5.0	19	i.p.	39.6	4.40	77.9	9.1	4.9	1.8	121
PG16	5.0	20	i.p.	40.6	4.38	71.3	13.2	6.1	2.2	110
PG16	5.0	21	i.p.	36.2	4.56	77.4	8.0	4.1	1.9	41
PG16	15	8	i.p.	15.6	3.51	76.4	10.4	4.4	2.4	88
PG16	15	9	i.p.	138.5	3.88	79.2	8.7	5.3	1.7	58
PG16	15	10	i.p.	91.6	4.80	78.6	7.9	4.0	2.0	182
PG16	15	11	i.p.	86.9	4.82	75.5	9.0	4.6	2.0	125
PG16	15	12	i.p.	23.4	4.29	77.2	9.6	4.6	2.1	51
PG16	15	13	i.p.	119.9	3.99	68.5	9.9	6.3	1.6	124
PG16	15	14	i.p.	66.8	4.57	77.7	8.5	4.6	1.8	126
PG16	50	1 [†]	i.p.	ND	ND	ND	ND	ND	ND	ND
PG16	50	2	i.p.	ND	ND	48.1	25.1	18.7	1.3	7
PG16	50	3	i.p.	142.9	4.35	69.6	13.8	6.4	2.1	72
PG16	50	4	i.p.	121.3	4.18	73.8	11.4	6.7	1.7	29
PG16	50	5	i.p.	95.9	4.69	73.2	11.1	7.5	1.5	32
PG16	50	6	i.p.	103.0	3.98	76.0	7.7	4.7	1.6	111
PG16	50	7	i.p.	100.7	4.02	70.8	11.2	6.9	1.6	101
Truvada	2000/1300 mg/kg	29	oral	77.0	4.73	81.0	6.7	4.2	1.6	89
Truvada	2000/1300 mg/kg	30	oral	56.2	4.79	78.2	9.1	4.7	1.9	121
Truvada	2000/1300 mg/kg	31	oral	60.3	4.68	81.2	7.4	4.5	1.7	37
Truvada	2000/1300 mg/kg	32	oral	113.6	3.80	77.6	9.1	7.3	1.2	21
Truvada	2000/1300 mg/kg	33	oral	47.0	4.69	79.4	7.9	5.5	1.4	31
Truvada	2000/1300 mg/kg	34	oral	66.1	3.61	81.7	6.4	3.9	1.6	101
Truvada	2000/1300 mg/kg	35	oral	71.8	4.14	76.4	9.6	4.8	2.0	71
NA	Mock-infected	43	NA	0.0	1.49	82.6	8.5	3.7	2.3	60
NA	Mock-infected	44	NA	0.0	<1.48	70.6	15.3	6.2	2.5	94
NA	Mock-infected	45	NA	0.0	<1.48	76.1	12.5	5.1	2.5	81
NA	Mock-infected	46	NA	0.0	<1.48	78.0	11.1	5.9	1.9	49
NA	Mock-infected	47	NA	0.0	<1.48	90.2	4.6	2.3	2.0	23
NA	Mock-infected	48	NA	0.0	<1.48	69.4	16.9	8.5	2.0	23
NA	Mock-infected	49	NA	0.0	<1.48	80.0	9.9	4.6	2.2	48

NA: Not applicable

ND: Not determined

[†] abnormal implant

Supplementary Table 11. Data for individual mice in Figure 6A (cohort generated with tissues from donor K).

Drug	Drug dose (μ g/dose, days from inoculation)	Mouse ID	Drug route	p24 (pg/ 10^6 cells)	HIV RNA (log ₁₀ copies/ 10^6 cells)	Thy/Liv Implant Cells				Total cell yield ($\times 10^6$)
						CD4 ⁺ CD8 ⁺ Double- positive (%)	CD4 Single- positive (%)	CD8 Single- positive (%)	CD4/CD8 ratio	
NA	Untreated	40	NA	561.3	5.30	55.4	16.3	9.6	1.7	6
NA	Untreated	41	NA	729.4	5.11	65.8	14.3	7.0	2.0	23
NA	Untreated	42	NA	951.1	5.64	67.4	14.5	6.8	2.1	11
NA	Untreated	43	NA	384.5	5.22	71.9	12.2	8.7	1.4	36
NA	Untreated	44	NA	647.1	5.47	66.4	13.3	7.8	1.7	25
NA	Untreated	45	NA	208.5	5.04	77.1	5.7	4.2	1.4	3
NA	Untreated	46	NA	898.4	5.55	41.5	24.2	14.7	1.6	42
PG16	5, -1	1	i.p.	423.5	4.86	77.1	11.0	5.1	2.2	44
PG16	5, -1	2	i.p.	346.5	5.00	76.6	11.3	5.0	2.2	55
PG16	5, -1	3	i.p.	0.0	1.58	80.0	9.6	3.7	2.6	71
PG16	5, -1	4	i.p.	15.3	4.73	80.7	8.8	3.8	2.3	36
PG16	5, -1	5	i.p.	516.3	5.32	80.0	9.2	3.7	2.5	6
PG16	5, +8	6	i.p.	608.9	5.34	75.9	10.9	5.4	2.0	45
PG16	5, +8	7	i.p.	337.7	5.37	68.8	14.4	8.7	1.7	11
PG16	5, +8	8	i.p.	179.7	4.79	75.8	11.8	6.3	1.9	78
PG16	5, +8	9	i.p.	162.9	4.41	74.7	11.4	7.2	1.6	51
PG16	5, +8	10	i.p.	294.6	4.78	77.3	8.8	6.6	1.3	47
PG16	5, +8	11	i.p.	300.9	5.27	72.2	10.1	7.4	1.4	23
PG16	5, +8	12	i.p.	140.7	4.86	75.4	9.6	6.3	1.5	34
PG16	5, +15	13	i.p.	101.6	4.34	75.2	10.5	6.3	1.7	32
PG16	5, +15	14	i.p.	86.6	4.38	66.1	14.9	10.6	1.4	6
PG16	5, +15	15	i.p.	453.8	5.11	38.7	36.1	12.9	2.8	22
PG16	5, +15	16	i.p.	407.5	5.31	46.0	25.8	16.1	1.6	23
PG16	5, +15	17	i.p.	188.6	4.58	72.2	11.5	7.2	1.6	18
PG16	5, +15	18	i.p.	619.7	5.35	30.1	35.3	23.3	1.5	9
PG16	5, +15	19	i.p.	193.1	4.39	71.0	13.5	7.7	1.7	21
PG16	50, +8	20	i.p.	258.2	4.82	78.2	5.8	4.4	1.3	14
PG16	50, +8	21	i.p.	295.2	5.01	74.0	12.0	7.0	1.7	45
PG16	50, +8	22	i.p.	567.1	5.68	64.7	15.0	10.9	1.4	67
PG16	50, +8	23	i.p.	266.5	4.79	66.1	14.1	9.7	1.5	34
PG16	50, +8	24 [†]	i.p.	ND	ND	ND	ND	ND	ND	ND
PG16	50, +8	25	i.p.	276.0	4.61	72.3	13.7	6.5	2.1	62
PG16	50, +8	26	i.p.	283.6	4.54	74.8	11.2	6.6	1.7	55
PG16	50, +15	27	i.p.	361.2	4.63	76.6	10.9	5.3	2.1	75
PG16	50, +15	28	i.p.	35.8	4.27	65.4	14.0	9.5	1.5	19
PG16	50, +15	29	i.p.	334.7	4.88	75.7	10.4	5.6	1.9	111
PG16	50, +15	30	i.p.	576.1	5.41	20.6	49.0	17.0	2.9	12
PG16	50, +15	31	i.p.	194.1	4.63	68.7	10.8	6.7	1.6	23
PG16	50, +15	32	i.p.	435.8	5.15	68.0	13.4	7.5	1.8	24
PG16	50, +15	33	i.p.	416.7	5.26	69.0	13.4	6.7	2.0	30
PG16	50, +22	34	i.p.	197.2	4.79	61.8	18.4	14.2	1.3	11
PG16	50, +22	35	i.p.	223.0	4.69	64.1	19.7	9.8	2.0	31
PG16	50, +22	36	i.p.	214.1	4.82	82.8	7.2	5.2	1.4	37
PG16	50, +22	37	i.p.	605.7	4.85	68.6	14.9	9.4	1.6	19
PG16	50, +22	38*	i.p.	ND	ND	ND	ND	ND	ND	ND
PG16	50, +22	39	i.p.	147.0	5.07	76.5	13.2	4.2	3.1	46
NA	Mock-infected	47	NA	0.0	<1.48	86.5	6.9	1.5	4.5	92
NA	Mock-infected	48	NA	0.0	<1.48	84.2	6.8	1.8	3.8	112
NA	Mock-infected	49	NA	0.0	<1.48	77.1	7.9	3.2	2.5	249
NA	Mock-infected	50	NA	0.0	<1.48	76.9	8.4	3.5	2.4	99

NA: Not applicable

ND: Not determined

* mouse died

[†] abnormal implant

Supplementary Table 12. Data for individual mice in Figure 6B (cohort generated with tissues from donor L).

Drug	Drug dose ($\mu\text{g}/\text{dose}$, termination weeks)	Mouse ID	Drug route	p24 ($\text{pg}/10^6$ cells)	HIV RNA (\log_{10} copies/ 10^6 cells)	Thy/Liv Implant Cells				Total cell yield ($\times 10^6$)
						CD4 ⁺ CD8 ⁺ Double- positive (%)	CD4 Single- positive (%)	CD8 Single- positive (%)	CD4/CD8 ratio	
NA	Untreated, 17	1	NA	296.5	5.25	72.9	10.0	7.7	1.3	111
NA	Untreated, 17	2	NA	75.8	4.65	80.7	7.5	5.3	1.4	111
NA	Untreated, 17	3 [†]	NA	ND	ND	ND	ND	ND	ND	ND
NA	Untreated, 17	4	NA	36.2	4.87	49.0	19.6	20.9	0.9	77
NA	Untreated, 17	5 [†]	NA	ND	ND	ND	ND	ND	ND	ND
NA	Untreated, 17	6	NA	198.5	5.02	75.9	11.3	4.2	2.7	196
PG16	500, 20	7 [†]	i.p.	ND	ND	ND	ND	ND	ND	ND
PG16	500, 20	8	i.p.	129.0	4.96	79.6	7.2	7.0	1.0	88
PG16	500, 20	9	i.p.	439.0	6.65	76.1	3.9	8.6	0.5	151
PG16	500, 20	10 [†]	i.p.	ND	ND	ND	ND	ND	ND	ND
PG16	500, 20	11	i.p.	375.9	5.65	75.7	7.1	7.3	1.0	169
PG16	500, 20	12	i.p.	265.8	5.20	80.0	6.6	4.8	1.4	404
PBS	0, 20	13	i.p.	274.2	5.15	78.2	6.9	6.7	1.0	78
PBS	0, 20	14	i.p.	445.9	5.83	67.8	9.3	10.5	0.9	119
PBS	0, 20	15	i.p.	177.9	5.81	77.4	7.9	6.6	1.2	371
PBS	0, 20	16	i.p.	497.6	5.59	71.2	8.2	7.3	1.1	129
PBS	0, 20	17	i.p.	140.2	5.27	81.5	5.4	5.3	1.0	151
PBS	0, 20	18	i.p.	241.1	5.72	79.6	5.3	6.4	0.8	111
PBS	0, 20	19	i.p.	331.2	5.84	73.0	7.5	10.7	0.7	47
NA	Mock-infected, 17	20	NA	0.0	<1.48	28.6	7.4	2.4	3.1	361
NA	Mock-infected, 17	21	NA	0.0	<1.48	85.3	7.1	2.2	3.2	346
NA	Mock-infected, 17	22	NA	0.0	<1.48	58.5	5.3	2.4	2.2	148
NA	Mock-infected, 17	23	NA	0.0	<1.48	31.2	9.3	2.7	3.5	357
NA	Mock-infected, 17	24 [†]	NA	ND	ND	ND	ND	ND	ND	ND
NA	Mock-infected, 20	25	NA	0.0	<1.48	83.5	6.8	4.4	1.5	389
NA	Mock-infected, 20	26	NA	0.0	<1.48	81.7	8.9	4.3	2.1	169
NA	Mock-infected, 20	27	NA	0.0	<1.48	76.2	11.7	6.5	1.8	264
NA	Mock-infected, 20	28	NA	0.0	<1.48	80.8	8.5	3.7	2.3	355
NA	Mock-infected, 20	29 [†]	NA	ND	ND	ND	ND	ND	ND	ND

NA: Not applicable

ND: Not determined

[†] abnormal implant

Supplementary Table 13. Data for individual mice in Figure 6C (cohort generated with tissues and CD34⁺ cells from donor M).

HIV RNA (log ₁₀ copies/10 ⁶ cells) and CD4 ⁺ T-cell count (cells/μl whole blood)															
Weeks after HIV inoculation															
Drug	Mouse ID	HIV _{JR-CSF} inoculum (TCID ₅₀)	Drug dose (μg/dose)	Drug route	Week 4		Week 6		Week 8		Week 10		Week 12		
					HIV RNA	CD4 ⁺ cells	HIV RNA	CD4 ⁺ cells	HIV RNA	CD4 ⁺ cells	HIV RNA	CD4 ⁺ cells	HIV RNA	CD4 ⁺ cells	
PG16	1	8,000	1.5	i.p.	4.17	278	4.09	198	4.33	141	3.94	21	4.14	39	
PG16	5	8,000	1.5	i.p.	4.41	212	4.06	77	3.82	101	3.87	17	3.80	8	
PG16	15	8,000	1.5	i.p.	4.62	64	4.04	50	4.34	52	NA*	NA*	NA*	NA*	
PG16	21	8,000	1.5	i.p.	3.94	38	3.70	14	4.46	41	5.00	34	NA*	NA*	
PG16	29	8,000	1.5	i.p.	4.48	164	3.75	64	3.99	40	4.16	37	4.08	47	
PG16	45	8,000	1.5	i.p.	4.02	40	3.96	40	3.94	15	4.26	7	3.96	5	
PBS	4	8,000	NA	i.p.	4.71	362	4.20	322	4.10	107	3.88	45	4.23	128	
PBS	14	8,000	NA	i.p.	4.35	64	3.77	64	4.20	8	4.49	3	NA*	NA*	
PBS	16	8,000	NA	i.p.	4.26	138	3.83	207	3.90	153	4.10	29	3.83	7	
PBS	24	8,000	NA	i.p.	4.23	95	3.99	57	4.08	107	4.30	84	4.06	62	
PBS	34	8,000	NA	i.p.	4.42	243	3.69	70	3.50	8	4.05	22	4.57	155	
PBS	38	8,000	NA	i.p.	4.31	63	3.96	69	3.92	94	3.80	45	4.03	56	
PBS	40	8,000	NA	i.p.	4.28	130	3.74	82	3.91	61	ND	ND	3.74	65	
NA	2	8,000	NA	NA	<1.88	621	ND	ND	<1.88	461	ND	ND	ND	740	
NA	3	8,000	NA	NA	<1.88	368	ND	ND	<1.88	324	ND	ND	ND	287	
NA	6	8,000	NA	NA	<1.88	321	ND	ND	<1.88	180	ND	ND	ND	280	
NA	7	8,000	NA	NA	2.02	217	ND	ND	<1.88	218	ND	ND	ND	364	
NA	8	8,000	NA	NA	<1.88	196	ND	ND	<1.88	116	ND	ND	ND	197	
NA	9	8,000	NA	NA	<1.88	209	ND	ND	<1.88	236	ND	ND	ND	174	
NA	10	8,000	NA	NA	<1.88	704	ND	ND	<1.88	507	ND	ND	ND	963	
NA	11	8,000	NA	NA	<1.88	183	ND	ND	<1.88	187	ND	ND	ND	233	
NA	12	8,000	NA	NA	<1.88	215	ND	ND	<1.88	127	ND	ND	ND	138	
NA	13	8,000	NA	NA	<1.88	432	ND	ND	<1.88	331	ND	ND	ND	191	
NA	17	8,000	NA	NA	<1.88	157	ND	ND	<1.88	153	ND	ND	ND	69	
NA	18	8,000	NA	NA	<1.88	92	ND	ND	<1.88	127	ND	ND	ND	57	
NA	19	8,000	NA	NA	<1.88	138	ND	ND	<1.88	184	ND	ND	ND	77	
NA	20	8,000	NA	NA	<1.88	171	ND	ND	<1.88	176	ND	ND	ND	149	
NA	22	8,000	NA	NA	<1.88	368	ND	ND	<1.88	556	ND	ND	ND	193	
NA	23	8,000	NA	NA	<1.88	120	ND	ND	<1.88	74	ND	ND	ND	91	
NA	25	8,000	NA	NA	<1.88	538	ND	ND	<1.88	482	ND	ND	ND	NA*	
NA	26	8,000	NA	NA	<1.88	291	ND	ND	2.29	538	ND	ND	ND	305	
NA	27	8,000	NA	NA	<1.88	527	ND	ND	<1.88	380	ND	ND	ND	226	
NA	28	8,000	NA	NA	<1.88	388	ND	ND	<1.88	396	ND	ND	ND	NA*	
NA	30	8,000	NA	NA	<1.88	444	ND	ND	1.90	236	ND	ND	ND	324	
NA	31	8,000	NA	NA	<1.88	833	ND	ND	<1.88	344	ND	ND	ND	506	
NA	32	8,000	NA	NA	1.90	353	ND	ND	<1.88	367	ND	ND	ND	312	
NA	33	8,000	NA	NA	<1.88	248	ND	ND	<1.88	245	ND	ND	ND	NA*	
NA	35	8,000	NA	NA	<1.88	380	ND	ND	2.79	383	ND	ND	ND	196	
NA	36	8,000	NA	NA	<1.88	283	ND	ND	<1.88	422	ND	ND	ND	319	
NA	37	8,000	NA	NA	<1.88	225	ND	ND	<1.88	373	ND	ND	ND	145	
NA	39	8,000	NA	NA	1.92	81	ND	ND	<1.88	224	ND	ND	ND	153	
NA	41	8,000	NA	NA	<1.88	251	ND	ND	<1.88	327	ND	ND	ND	272	
NA	42	8,000	NA	NA	<1.88	450	ND	ND	<1.88	689	ND	ND	ND	64	
NA	43	8,000	NA	NA	<1.88	320	ND	ND	<1.88	321	ND	ND	ND	78	
NA	44	8,000	NA	NA	<1.88	188	ND	ND	<1.88	323	ND	ND	ND	122	
NA	46	8,000	NA	NA	<1.88	140	ND	ND	<1.88	222	ND	ND	ND	154	
NA	47	8,000	NA	NA	<1.88	216	ND	ND	<1.88	278	ND	ND	ND	341	
NA	48	NA	NA	NA	<1.88	191	<1.88	279	<1.88	244	<1.88	247	ND	319	
NA	49	NA	NA	NA	<1.88	81	<1.88	111	<1.88	182	<1.88	113	ND	177	
NA	50	NA	NA	NA	<1.88	218	<1.88	205	<1.88	233	<1.88	167	ND	98	
NA	51	NA	NA	NA	<1.88	265	<1.88	638	<1.88	316	<1.88	242	ND	NA*	
NA	52	NA	NA	NA	<1.88	309	<1.88	366	<1.88	324	<1.88	329	ND	412	
NA	53	NA	NA	NA	<1.88	257	<1.88	404	<1.88	467	<1.88	221	ND	851	
NA	54	NA	NA	NA	<1.88	84	<1.88	105	<1.88	91	<1.88	68	ND	74	
NA	55 [†]	8,000	NA	NA	<1.88	80	ND	ND	<1.88	54	ND	ND	ND	NA*	
NA	56 [†]	8,000	NA	NA	<1.88	4	ND	ND	<1.88	3	ND	ND	ND	0	
NA	57 [†]	8,000	NA	NA	<1.88	94	ND	ND	<1.88	151	ND	ND	ND	173	
NA	58 [†]	8,000	NA	NA	<1.88	22	ND	ND	<1.88	16	ND	ND	ND	9	
NA	59 [†]	8,000	NA	NA	<1.88	7	ND	ND	<1.88	2	ND	ND	ND	0	

NA: Not applicable

ND: Not determined

*mouse died

[†]NSG-hu Thy/Liv mice; not injected with human CD34⁺ cells.